Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rolicyclidine is a dissociative anesthetic drug belonging to the arylcyclohexylamine class. It exhibits hallucinogenic and sedative properties similar to phencyclidine (PCP), but is slightly less potent and has fewer stimulant effects. Its pharmacological profile includes inducing sedation reminiscent of barbiturates while retaining dissociative and hallucinogenic characteristics typical of PCP-like substances. The primary mechanism of action is antagonism at the N-methyl-D-aspartate (NMDA) receptor, leading to altered sensory perception and a sense of detachment from the environment. Additional interactions with dopamine receptors have been reported, contributing further to its psychoactive effects. Due to its similarity with PCP in both structure and effect profile, rolicyclidine was classified as a Schedule I controlled substance in several jurisdictions during the 1970s; however, it was never widely abused or used clinically[1][2][3][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rolicyclidine.